2. Clinical Trial Phases Explained: First-in-Human to Phase IV
After this lesson you can
- State the question, typical size and duration of each phase
- Walk a dose-finding cohort through the three-plus-three rule to the maximum tolerated dose
- Explain why a promising phase two result is not evidence of benefit
- Distinguish a pilot study from a phase two trial
- Explain why rare harms appear only in wide use
Video coming soon
Lessons publish daily from November 17, 2026.
This lesson walks the four phases of development, from first-in-human safety and dose finding through activity screening, confirmatory trials and surveillance in wide use. It works a fictional dose-finding study with the three-plus-three rule and places a non-drug support program on the same ladder by analogy.
Questions and answers
Questions a learner would ask about this lesson. Think through your own answer before you open each one.
- What question does each phase of development ask?
Show answer
Phase one asks whether people can tolerate the intervention and at what dose. Phase two asks whether it shows activity. Phase three asks whether it works against a control, and phase four asks what happens in wide use. Size grows from tens of participants to thousands or more as the evidence grows.
- How does the three-plus-three rule work?
Show answer
Three people are treated at a dose level. If none of three has a dose-limiting toxicity, the study escalates; if one of three does, that level is expanded to six; if two or more do, the study stops and the maximum tolerated dose is the level below. After an expansion, one of six allows escalation and two or more of six means stop.
- Why isn't a promising phase two result evidence of benefit?
Show answer
Phase two is a screen built to let signals through. Small samples produce large chance effects, short endpoints may not predict long ones, and selected participants may not represent the population. A single-arm phase two also cannot separate the intervention from regression to the mean and the natural course of the condition.
- Is a pilot study the same as phase two?
Show answer
No. A pilot asks whether the trial can be run: recruitment, delivery, retention and measurement. Phase two asks whether the intervention shows activity. A pilot is not sized to detect anything.
- Do phases apply to a behavioral program that has no dose in milligrams?
Show answer
Yes, by analogy. The program has a dose in sessions, length and intensity, and it can cause harm through time, cost or distress. In the fictional Oakhaven case, the pilot served as the activity stage, the 250-person trial is the confirmatory stage, and district-wide adoption with monitoring is the fourth rung.
Practice quiz
- Question 1In the three-plus-three rule, one dose-limiting toxicity among the first three at a dose level means:
- Question 2In the Oakhaven dose-finding side case: level one 0 of 3, level two 0 of 3, level three 1 of 3 then 1 of 6, level four 2 of 3. What is the maximum tolerated dose?
- Question 3At an expanded level of six participants, what result tells the study to stop?
- Question 4The main question of phase three is:
- Question 5A single-arm study shows improvement from baseline. What can it not separate from the intervention's own effect?
- Question 6Phase four studies exist mainly to detect:
- Question 7A trial of 250 people reports zero cases of a harm. What does the lesson say this shows?
- Question 8What does "confirmatory" mean in phase three?
- Question 9Which is a safeguard built into a first-in-human protocol?
- Question 10Oakhaven recruits 25 participants per month for ten months, and each is followed for twelve months. About how long does the trial run?
Saved in your browser only: no account, no server.
Design of Clinical Studies is education only. Every lesson follows the fictional Oakhaven Adherence Trial with invented numbers; the course uses no real data and cites no real studies.